{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:17:44Z","timestamp":1773249464545,"version":"3.50.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bulcan.2025.07.017","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:14:32Z","timestamp":1757452472000},"page":"412-422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["De la biologie des tumeurs de la granulosa de l\u2019ovaire \u00e0 la perspective de nouvelles th\u00e9rapeutiques au-del\u00e0 de la chimioth\u00e9rapie"],"prefix":"10.1016","volume":"113","author":[{"given":"Sil","family":"Endale Ahanda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Lain\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brunhilde","family":"Hanvic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quentin","family":"Verdet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9a","family":"Ikhlef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"De Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Fieuws","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Cumunel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Chopin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Rousset-Jablonski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9a","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Meeus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Agathe","family":"Serre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Treilleux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Le Saux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2025.07.017_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2007.08.007","article-title":"Granulosa cell tumor of the ovary","volume":"34","author":"Pectasides","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0010","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0015","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2003.10.019","article-title":"Granulosa cell tumor of the ovary","volume":"21","author":"Schumer","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0020","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1200\/JCO.2007.11.1005","article-title":"Management of ovarian stromal cell tumors","volume":"25","author":"Colombo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0025","first-page":"1223","article-title":"Granulosa cell tumor of the ovary: 10\u00a0years follow-up data of 65\u00a0patients","volume":"24","author":"Sehouli","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/IGC.0000000000000304","article-title":"Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor a 56-year single-center experience","volume":"25","author":"Bryk","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0035","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw134","article-title":"Molecularly defined adult granulosa cell tumor of the ovary: the clinical phenotype","volume":"108","author":"McConechy","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0040","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/07853890.2017.1294760","article-title":"Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary","volume":"49","author":"F\u00e4rkkil\u00e4","year":"2017","journal-title":"Ann Med"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0045","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ygyno.2023.05.014","article-title":"Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salom\u00e9 study including 469\u00a0patients. A TMRG and GINECO group study","volume":"174","author":"Hanvic","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0050","first-page":"355","article-title":"A temporary response of recurrent granulosa cell tumor to adriamycin","volume":"52","author":"Disaia","year":"1978","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0055","first-page":"765","article-title":"Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide","volume":"70","author":"Gershenson","year":"1987","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0060","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2004.12.074","article-title":"The activity of taxanes in the treatment of sex cord-stromal ovarian tumors","volume":"22","author":"Brown","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0065","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ygyno.2005.01.011","article-title":"The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors","volume":"97","author":"Brown","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0070","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.3390\/cancers14122998","article-title":"Response to systemic therapies in ovarian adult granulosa cell tumors: a literature review","volume":"14","author":"Brink","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0075","first-page":"515","article-title":"Ovarian granulosa-stromal cell tumors are characterized by trisomy 12","volume":"138","author":"Fletcher","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0080","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/01.MP.0000024290.55261.14","article-title":"Characteristic pattern of genetic aberrations in ovarian granulosa cell tumors","volume":"15","author":"Mayr","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ygyno.2004.12.014","article-title":"Molecular cytogenetics of ovarian granulosa cell tumors by comparative genomic hybridization","volume":"97","author":"Lin","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0090","first-page":"3495","article-title":"Adult-type granulosa cell tumor of the ovary","volume":"12","author":"Li","year":"2022","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0095","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1056\/NEJMoa0902542","article-title":"Mutation of FOXL2\u00a0in granulosa-cell tumors of the ovary","volume":"360","author":"Shah","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0100","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2013.10.013","article-title":"Impact of a second opinion using expression and molecular analysis of FOXL2\u00a0for sex cord-stromal tumors. A study of the GINECO group & the TMRO network","volume":"132","author":"Maillet","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1158\/0008-5472.CAN-22-1880","article-title":"The oncogenic FOXL2\u00a0C134W mutation is a key driver of granulosa cell tumors","volume":"83","author":"Llano","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.18632\/oncotarget.27447","article-title":"FOXL2\u00a0homozygous genotype and chromosome instability are associated with recurrence in adult granulosa cell tumors of the ovary","volume":"11","author":"Kraus","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0115","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/path.5771","article-title":"FOXL2\u00a0in adult-type granulosa cell tumour of the ovary: oncogene or tumour suppressor gene?","volume":"255","author":"Pilsworth","year":"2021","journal-title":"J Pathol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0120","doi-asserted-by":"crossref","first-page":"e104719","DOI":"10.15252\/embj.2020104719","article-title":"An alternative miRISC targets a cancer-associated coding sequence mutation in FOXL2","volume":"39","author":"Shin","year":"2020","journal-title":"EMBO J"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0125","doi-asserted-by":"crossref","first-page":"e107517","DOI":"10.15252\/embj.2020107517","article-title":"Reply to \u201can alternative miRISC targets a cancer-associated coding sequence mutation in FOXL2\u201d","volume":"40","author":"Veitia","year":"2021","journal-title":"EMBO J"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0130","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1158\/0008-5472.CAN-20-0104","article-title":"The pathognomonic FOXL2\u00a0C134W mutation alters DNA-binding specificity","volume":"80","author":"Carles","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0135","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1158\/0008-5472.CAN-20-0259","article-title":"Mutant FOXL2C134W hijacks SMAD4\u00a0and SMAD2\/3\u00a0to drive adult granulosa cell tumors","volume":"80","author":"Weis-Banke","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0140","article-title":"Abstract CT109: livmoniplimab and budigalimab combination therapy in treating patients with metastatic ovarian granulosa cell tumors: results from dose escalation in a first-in-human study","volume":"14","author":"Rivera","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0145","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-19-1065","article-title":"First-in-human phase I study of the activin a inhibitor, STM 434, in patients with granulosa cell ovarian cancer and other advanced solid tumors","volume":"25","author":"Tao","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0150","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/1878-0261.13146","article-title":"Dual inhibition of TGF-\u03b2 and PD-L1: a novel approach to cancer treatment","volume":"16","author":"Gulley","year":"2022","journal-title":"Mol Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0155","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.gore.2018.05.013","article-title":"Treatment of recurrent granulosa cell tumor with metformin and letrozole, a case report","volume":"25","author":"Rush","year":"2018","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0160","first-page":"4885","article-title":"Mechanisms of metformin inhibiting cancer invasion and migration","volume":"12","author":"Chen","year":"2020","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0165","doi-asserted-by":"crossref","first-page":"e136773","DOI":"10.1172\/jci.insight.136773","article-title":"Ovarian granulosa cell tumor characterization identifies FOXL2\u00a0as an immunotherapeutic target","volume":"5","author":"Pierini","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0170","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ygyno.2025.02.018","article-title":"Signal transduction pathway activity in adult-type granulosa cell tumor samples","volume":"195","author":"Brink","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0175","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1016\/j.ygyno.2023.06.190","article-title":"Trial in progress: a phase two trial of nirogacestat, a gamma-secretase inhibitor, in patients with recurrent ovarian granulosa cell tumors (NCT05348356) (1284)","volume":"176","author":"Konstantinopoulos","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0180","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ymthe.2019.11.028","article-title":"CAR T cells targeting MISIIR for the treatment of ovarian cancer and other gynecologic malignancies","volume":"28","author":"Rodriguez-Garcia","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0185","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/ijgc-2018-000065","article-title":"Emerging biomarkers in ovarian granulosa cell tumors","volume":"29","author":"Mills","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0190","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/pgp.0b013e31805c0d99","article-title":"Estrogen receptor \u03b1 and progesterone receptor expression in ovarian adult granulosa cell tumors and sertoli-leydig cell tumors","volume":"26","author":"Farinola","year":"2007","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0195","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1210\/me.2006-0248","article-title":"Foxl2\u00a0up-regulates aromatase gene transcription in a female-specific manner by binding to the promoter as well as interacting with Ad4\u00a0binding protein\/steroidogenic factor 1","volume":"21","author":"Wang","year":"2007","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0200","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2018.05.013","article-title":"Estrogen receptor \u03b2: potential target for therapy in adult granulosa cell tumors?","volume":"150","author":"Ciucci","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0205","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.biocel.2016.01.003","article-title":"Impact of FOXL2\u00a0mutations on signaling in ovarian granulosa cell tumors","volume":"72","author":"Leung","year":"2016","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0210","doi-asserted-by":"crossref","first-page":"e14389","DOI":"10.1371\/journal.pone.0014389","article-title":"Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter","volume":"5","author":"Fleming","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0215","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/1541-7786.MCR-22-0623","article-title":"Comparative tumor microenvironment analysis of primary and recurrent ovarian granulosa cell tumors","volume":"21","author":"Khlebus","year":"2023","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0220","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2014.03.573","article-title":"Hormone therapy in ovarian granulosa cell tumors: a systematic review","volume":"134","author":"Van Meurs","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0225","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2021.07.024","article-title":"A phase 2\u00a0study of anastrozole in patients with oestrogen receptor and\/progesterone receptor positive recurrent\/metastatic granulosa cell tumours\/sex-cord stromal tumours of the ovary: the PARAGON\/ANZGOG 0903\u00a0trial","volume":"163","author":"Banerjee","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0230","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1210\/me.2009-0375","article-title":"FOXL2\u00a0interacts with steroidogenic factor-1 (SF-1) and represses SF-1-induced CYP17\u00a0transcription in granulosa cells","volume":"24","author":"Park","year":"2010","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0235","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1007\/s12094-023-03085-w","article-title":"Open-label phase II clinical trial of ketoconazole as CYP17\u00a0inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03","volume":"25","author":"Garc\u00eda-Donas","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0240","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ygyno.2024.10.019","article-title":"Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: the GREKO III study (GETHI2016-01)","volume":"191","author":"Garc\u00eda-Donas","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0245","doi-asserted-by":"crossref","first-page":"101118","DOI":"10.1016\/j.gore.2022.101118","article-title":"A case series of triplet anti-hormonal therapy in androgen receptor-positive recurrent adult ovarian granulosa cell tumor","volume":"44","author":"Summey","year":"2022","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0250","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqad063","article-title":"ER\u03b2 in granulosa cell tumors and its clinical potential","volume":"164","author":"Birgersson","year":"2023","journal-title":"Endocrinology"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0255","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0260","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0265","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13058-022-01510-6","article-title":"Cellular mechanisms underlying response and resistance to CDK4\/6\u00a0inhibitors in the treatment of hormone receptor-positive breast cancer","volume":"24","author":"Watt","year":"2022","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0270","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.3390\/cancers13123035","article-title":"Inhibition of CDK4\/6\u00a0as therapeutic approach for ovarian cancer patients: current evidences and future perspectives","volume":"13","author":"Dall\u2019Acqua","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0275","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","article-title":"CDK4\/6\u00a0inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US food and drug administration pooled analysis","volume":"21","author":"Gao","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0280","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6\u00a0inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0285","doi-asserted-by":"crossref","first-page":"101297","DOI":"10.1016\/j.gore.2023.101297","article-title":"Efficacy of cyclin-dependent kinase 4\/6\u00a0inhibitors in combination with hormonal therapy in patients with recurrent granulosa cell tumor of the ovary: a case series","volume":"50","author":"Albright","year":"2023","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0290","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ygyno.2023.05.040","article-title":"P13\u00a0ovarian granulosa cell tumors treated with oestrogen blockade and CDK4\/6\u00a0inhibitors: a case series","volume":"173","author":"Nanez","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0295","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/ijgc-2023-005189","article-title":"A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with oestrogen receptor-positive rare ovarian cancer: ALEPRO trial","volume":"34","author":"Ottenbourgs","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0300","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ygyno.2009.04.021","article-title":"Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors","volume":"114","author":"Tao","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0305","doi-asserted-by":"crossref","first-page":"E1973","DOI":"10.1210\/jc.2011-1812","article-title":"Serum vascular endothelial growth factor a (VEGF) is elevated in patients with ovarian granulosa cell tumor (GCT), and VEGF inhibition by bevacizumab induces apoptosis in GCT in vitro","volume":"96","author":"F\u00e4rkkil\u00e4","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0310","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1530\/EJE-10-0849","article-title":"Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2\u00a0are highly expressed in ovarian granulosa cell tumors","volume":"164","author":"F\u00e4rkkil\u00e4","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0315","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1470-2045(10)70232-1","article-title":"Biomarkers to predict the clinical efficacy of bevacizumab in cancer","volume":"11","author":"Jubb","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0320","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ygyno.2008.07.015","article-title":"The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report","volume":"111","author":"Kesterson","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0325","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cncr.28421","article-title":"Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2\u00a0trial of the gynecologic oncology group","volume":"120","author":"Brown","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0330","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1001\/jamaoncol.2020.4574","article-title":"Effect of weekly paclitaxel with or without bevacizumab on progression-free rate among patients with relapsed ovarian sex cord-stromal tumors\u00a0: the ALIENOR\/ENGOT-ov7\u00a0randomized clinical trial","volume":"6","author":"Ray-Coquard","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0335","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41379-018-0007-9","article-title":"TERT promoter mutation in adult granulosa cell tumor of the ovary","volume":"31","author":"Pilsworth","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0340","article-title":"TERT promoter mutations and survival outcomes in adult-type granulosa cell tumors","volume":"35","author":"Brodsky","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0345","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1158\/1541-7786.MCR-18-0359","article-title":"Mutational landscape of ovarian adult granulosa cell tumors from whole exome and targeted TERT promoter sequencing","volume":"17","author":"Alexiadis","year":"2019","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0350","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1038\/s41467-018-04950-x","article-title":"KMT2D\/MLL2\u00a0inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary","volume":"9","author":"Hillman","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0355","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.18632\/oncotarget.27988","article-title":"Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors","volume":"12","author":"Dhar","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0360","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1158\/2159-8290.CD-19-1448","article-title":"CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade","volume":"10","author":"Wang","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0365","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1158\/0008-5472.CAN-16-0481","article-title":"Reduced expression of histone methyltransferases KMT2C and KMT2D correlates with improved outcome in pancreatic ductal adenocarcinoma","volume":"76","author":"Dawkins","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0370","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1080\/15592294.2019.1634985","article-title":"Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3","volume":"14","author":"Lv","year":"2019","journal-title":"Epigenetics"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0375","doi-asserted-by":"crossref","first-page":"11564","DOI":"10.1200\/JCO.2020.38.15_suppl.11564","article-title":"Efficacy, safety, and immune priming effect of tazemetostat in patients with epithelioid sarcoma","volume":"38","author":"Gounder","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0380","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.3390\/cancers12082112","article-title":"Epithelioid sarcoma\u00a0\u2014\u00a0from genetics to clinical practice","volume":"12","author":"Czarnecka","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0385","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood.2020008743","article-title":"KDM5\u00a0inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas","volume":"138","author":"Heward","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0390","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nrd4154","article-title":"Histone lysine demethylases as targets for anticancer therapy","volume":"12","author":"H\u00f8jfeldt","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0395","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3390\/cancers12051308","article-title":"Whole genome analysis of ovarian granulosa cell tumors reveals tumor heterogeneity and a high-grade TP53-specific subgroup","volume":"12","author":"Roze","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0400","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ygyno.2021.06.024","article-title":"Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors","volume":"162","author":"Hillman","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0405","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc.2017.109","article-title":"Targeting mutant p53\u00a0for efficient cancer therapy","volume":"18","author":"Bykov","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0410","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw368.29","article-title":"PISARRO: a EUTROC phase 1b study of APR-246\u00a0with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high-grade serous ovarian cancer (HGSOC)","volume":"27","author":"Basu","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0415","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bulcan.2015.09.011","article-title":"La voie de signalisation PI3K-AKT-mTOR: description, d\u00e9veloppement th\u00e9rapeutique, r\u00e9sistances, marqueurs pr\u00e9dictifs\/pronostiques et applications th\u00e9rapeutiques en canc\u00e9rologie","volume":"103","author":"Brotelle","year":"2016","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0420","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase\u00a0\u2013\u00a0AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0425","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.pathol.4.110807.092311","article-title":"PTEN and the PI3-kinase pathway in cancer","volume":"4","author":"Chalhoub","year":"2009","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0430","doi-asserted-by":"crossref","first-page":"819128","DOI":"10.3389\/fonc.2022.819128","article-title":"PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway?","volume":"12","author":"Peng","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0435","doi-asserted-by":"crossref","first-page":"e0117769","DOI":"10.1371\/journal.pone.0117769","article-title":"Promotion of ovarian follicle growth following mTOR activation: synergistic effects of AKT stimulators","volume":"10","author":"Cheng","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0440","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1447-0756.2009.01127.x","article-title":"Granulosa cell tumor with activated mTOR-HIF-1\u03b1-VEGF pathway","volume":"36","author":"Miyazawa","year":"2010","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0445","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1158\/0008-5472.CAN-15-3358","article-title":"Constitutive activation of PI3K in oocyte induces ovarian granulosa cell tumors","volume":"76","author":"Kim","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0450","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ygyno.2016.12.016","article-title":"Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells","volume":"144","author":"Haltia","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0455","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3390\/cancers13030368","article-title":"In vitro systematic drug testing reveals carboplatin paclitaxel, and alpelisib as a potential novel combination treatment for adult granulosa cell tumors","volume":"13","author":"Roze","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0460","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3849","article-title":"Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes","volume":"49","author":"Wang","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0465","doi-asserted-by":"crossref","first-page":"6687","DOI":"10.1093\/hmg\/ddv373","article-title":"Molecular analyses of juvenile granulosa cell tumors bearing AKT1\u00a0mutations provide insights into tumor biology and therapeutic leads","volume":"24","author":"Auguste","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0470","doi-asserted-by":"crossref","first-page":"LB173","DOI":"10.1158\/1538-7445.AM2024-LB173","article-title":"Abstract LB173: discovery of ALTA-2618, the first allosteric, mutant-selective targeted therapy for AKT1\u00a0E17K driven cancers","volume":"84","author":"Murphy","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0475","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41418-023-01132-1","article-title":"Lineage tracing of mutant granulosa cells reveals in vivo protective mechanisms that prevent granulosa cell tumorigenesis","volume":"30","author":"Niu","year":"2023","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0480","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1200\/JCO.2022.40.16_suppl.5572","article-title":"Potential clinical activity of pembrolizumab monotherapy in ovarian sex cords, rare epithelial carcinoma, and other rare ovarian tumor histotypes: the French AcS\u00e9 pembrolizumab study from Unicancer","volume":"40","author":"Ray-Coquard","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0485","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10637-020-01043-9","article-title":"The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial","volume":"39","author":"How","year":"2021","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0490","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/s41379-020-0514-3","article-title":"Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary","volume":"33","author":"Da Cruz Paula","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.bulcan.2025.07.017_bib0495","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.bulcan.2023.03.007","article-title":"Avanc\u00e9es th\u00e9rapeutiques dans la prise en charge des tumeurs rares malignes ovariennes","volume":"110","author":"Lebreton","year":"2023","journal-title":"Bull Cancer (Paris)"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512500390X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512500390X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:14:22Z","timestamp":1773177262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745512500390X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S000745512500390X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.07.017","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De la biologie des tumeurs de la granulosa de l\u2019ovaire \u00e0 la perspective de nouvelles th\u00e9rapeutiques au-del\u00e0 de la chimioth\u00e9rapie","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}